Oruka Therapeutics, Inc. (ORKA)
2025-06-30 | ||||
|---|---|---|---|---|
| Net change in unrealized gains (losses) on marketable securities | -21 | |||
| Research and development | 24,087 | |||
| General and administrative | 4,342 | |||
| Total operating expenses | 28,429 | |||
| Loss from operations | -28,429 | |||
| Other expense, net | 2 | |||
| Interest income | 3,857 | |||
| Interest expense | - | |||
| Total other income (expense), net | 3,855 | |||
| Net loss | -24,574 | |||
| Comprehensive loss | -24,595 | |||
| Net loss per share attributable to stockholders, basic (in dollars per share) | -0.46 | |||
| Net loss per share attributable to stockholders, diluted (in dollars per share) | -0.46 | |||
| Weighted-average shares used in computing net loss per share attributable to stockholders, basic (in shares) | 42,095,951 | |||
| Weighted-average shares used in computing net loss per share attributable to stockholders, diluted (in shares) | 42,095,951 | |||